FI104429B - Uttrycksplasmider, som innefattar promotorer deo och bakterievärdceller, som innefattar dessa plasmider - Google Patents
Uttrycksplasmider, som innefattar promotorer deo och bakterievärdceller, som innefattar dessa plasmider Download PDFInfo
- Publication number
- FI104429B FI104429B FI883749A FI883749A FI104429B FI 104429 B FI104429 B FI 104429B FI 883749 A FI883749 A FI 883749A FI 883749 A FI883749 A FI 883749A FI 104429 B FI104429 B FI 104429B
- Authority
- FI
- Finland
- Prior art keywords
- plasmid
- deo
- sequence
- pmf
- polypeptide
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 661
- 230000001580 bacterial effect Effects 0.000 title claims description 17
- 239000013613 expression plasmid Substances 0.000 title claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 245
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 165
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 164
- 229920001184 polypeptide Polymers 0.000 claims abstract description 162
- 241000588724 Escherichia coli Species 0.000 claims abstract description 147
- 108020004414 DNA Proteins 0.000 claims abstract description 108
- 239000010949 copper Substances 0.000 claims abstract description 54
- 108010000521 Human Growth Hormone Proteins 0.000 claims abstract description 45
- 102000002265 Human Growth Hormone Human genes 0.000 claims abstract description 45
- 229910052802 copper Inorganic materials 0.000 claims abstract description 41
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000000854 Human Growth Hormone Substances 0.000 claims abstract description 36
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 32
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 31
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 claims abstract description 31
- 230000012010 growth Effects 0.000 claims abstract description 27
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 107
- 108010006025 bovine growth hormone Proteins 0.000 claims description 95
- 210000003705 ribosome Anatomy 0.000 claims description 75
- 239000002609 medium Substances 0.000 claims description 64
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 57
- 239000008103 glucose Substances 0.000 claims description 53
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 52
- 238000004519 manufacturing process Methods 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 34
- 102000018997 Growth Hormone Human genes 0.000 claims description 33
- 108010051696 Growth Hormone Proteins 0.000 claims description 33
- 150000001413 amino acids Chemical group 0.000 claims description 30
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 30
- 229960000723 ampicillin Drugs 0.000 claims description 30
- 229930091371 Fructose Natural products 0.000 claims description 29
- 239000005715 Fructose Substances 0.000 claims description 29
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 29
- 239000000122 growth hormone Substances 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 26
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 23
- 102000006635 beta-lactamase Human genes 0.000 claims description 23
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 239000011701 zinc Substances 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 18
- 102000053602 DNA Human genes 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 15
- 239000003623 enhancer Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 108020004705 Codon Proteins 0.000 claims description 12
- 108091081024 Start codon Proteins 0.000 claims description 11
- 150000002500 ions Chemical class 0.000 claims description 11
- 108091008146 restriction endonucleases Proteins 0.000 claims description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 9
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 239000001540 sodium lactate Substances 0.000 claims description 8
- 229940005581 sodium lactate Drugs 0.000 claims description 8
- 235000011088 sodium lactate Nutrition 0.000 claims description 8
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 7
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- 241000588722 Escherichia Species 0.000 claims description 6
- OHVGNSMTLSKTGN-BTVCFUMJSA-N [C].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [C].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O OHVGNSMTLSKTGN-BTVCFUMJSA-N 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 241001515965 unidentified phage Species 0.000 claims description 6
- 102000007592 Apolipoproteins Human genes 0.000 claims description 5
- 108010071619 Apolipoproteins Proteins 0.000 claims description 5
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 claims description 5
- 235000019265 sodium DL-malate Nutrition 0.000 claims description 5
- 239000001394 sodium malate Substances 0.000 claims description 5
- 238000013519 translation Methods 0.000 claims description 5
- 238000005273 aeration Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 230000003362 replicative effect Effects 0.000 claims description 3
- 230000004543 DNA replication Effects 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-M sodium lactate Chemical compound [Na+].CC(O)C([O-])=O NGSFWBMYFKHRBD-UHFFFAOYSA-M 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 117
- 102100029470 Apolipoprotein E Human genes 0.000 abstract description 13
- 101710095339 Apolipoprotein E Proteins 0.000 abstract description 13
- 230000004927 fusion Effects 0.000 abstract description 11
- 102000009661 Repressor Proteins Human genes 0.000 abstract description 8
- 108010034634 Repressor Proteins Proteins 0.000 abstract description 8
- 241000283690 Bos taurus Species 0.000 abstract description 4
- 102100037362 Fibronectin Human genes 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 description 204
- 102000004169 proteins and genes Human genes 0.000 description 98
- 229940023064 escherichia coli Drugs 0.000 description 89
- 235000018102 proteins Nutrition 0.000 description 89
- 238000000605 extraction Methods 0.000 description 36
- 239000004098 Tetracycline Substances 0.000 description 33
- 229960002180 tetracycline Drugs 0.000 description 33
- 229930101283 tetracycline Natural products 0.000 description 33
- 235000019364 tetracycline Nutrition 0.000 description 33
- 150000003522 tetracyclines Chemical class 0.000 description 33
- 239000000499 gel Substances 0.000 description 30
- 239000013598 vector Substances 0.000 description 30
- 238000010276 construction Methods 0.000 description 27
- 238000000855 fermentation Methods 0.000 description 26
- 230000004151 fermentation Effects 0.000 description 26
- 108091026890 Coding region Proteins 0.000 description 25
- 239000013604 expression vector Substances 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 21
- 238000003776 cleavage reaction Methods 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 19
- 230000007017 scission Effects 0.000 description 19
- 238000012546 transfer Methods 0.000 description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 229910052799 carbon Inorganic materials 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- 101150017120 sod gene Proteins 0.000 description 16
- 102000013918 Apolipoproteins E Human genes 0.000 description 15
- 108010025628 Apolipoproteins E Proteins 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 230000014759 maintenance of location Effects 0.000 description 15
- 210000000349 chromosome Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 12
- 238000001962 electrophoresis Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 10
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 10
- 229960004452 methionine Drugs 0.000 description 10
- 229920002401 polyacrylamide Polymers 0.000 description 10
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 229930182817 methionine Natural products 0.000 description 9
- 235000006109 methionine Nutrition 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- JQECLVNLAZGHRQ-CIUDSAMLSA-N Met-Asp-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O JQECLVNLAZGHRQ-CIUDSAMLSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 241001400590 Richia Species 0.000 description 7
- 238000012300 Sequence Analysis Methods 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 241001340534 Eido Species 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000002497 phase alternated rotation of magnetisation Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 5
- 101710154303 Cyclic AMP receptor protein Proteins 0.000 description 5
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 5
- 108090000364 Ligases Proteins 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000001925 catabolic effect Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 235000004554 glutamine Nutrition 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 229910017518 Cu Zn Inorganic materials 0.000 description 4
- 229910017752 Cu-Zn Inorganic materials 0.000 description 4
- 229910017943 Cu—Zn Inorganic materials 0.000 description 4
- 241001288713 Escherichia coli MC1061 Species 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 239000006142 Luria-Bertani Agar Substances 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101000742291 Bifidobacterium adolescentis (strain ATCC 15703 / DSM 20083 / NCTC 11814 / E194a) Reducing end xylose-releasing exo-oligoxylanase Proteins 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108700023157 Galactokinases Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 3
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 3
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000000326 densiometry Methods 0.000 description 3
- 238000010217 densitometric analysis Methods 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 2
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 244000182625 Dictamnus albus Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102100022404 E3 ubiquitin-protein ligase Midline-1 Human genes 0.000 description 2
- 101710102210 E3 ubiquitin-protein ligase Midline-1 Proteins 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000048120 Galactokinases Human genes 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 101150025129 POP1 gene Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 108091006374 cAMP receptor proteins Proteins 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000003111 growth hormone derivative Substances 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000002213 purine nucleotide Substances 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000011172 small scale experimental method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000003351 stiffener Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940032362 superoxide dismutase Drugs 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910001868 water Inorganic materials 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 101150106774 9 gene Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241001479434 Agfa Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 241000566113 Branta sandvicensis Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101000928995 Caenorhabditis elegans Putative deoxyribose-phosphate aldolase Proteins 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000010567 DNA Polymerase II Human genes 0.000 description 1
- 108010063113 DNA Polymerase II Proteins 0.000 description 1
- KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical compound O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 108010074124 Escherichia coli Proteins Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 101150117524 GPX gene Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000868115 Homo sapiens Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101710105045 Lipoprotein E Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102100036629 Phosphoglucomutase-2 Human genes 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 101100373202 Rattus norvegicus Cx3cl1 gene Proteins 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- 101710145752 Serine recombinase gin Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000005321 cobalt glass Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 102000030794 deoxyribose-phosphate aldolase Human genes 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- GEPAYBXVXXBSKP-SEPHDYHBSA-L disodium;5-isothiocyanato-2-[(e)-2-(4-isothiocyanato-2-sulfonatophenyl)ethenyl]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S([O-])(=O)=O GEPAYBXVXXBSKP-SEPHDYHBSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 108010022192 endodeoxyribonuclease NdeI Proteins 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000003804 extraction from natural source Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 108010001722 phosphopentomutase Proteins 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 101150055349 sor gene Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000005533 tritiation Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Claims (14)
1. Uttrycksplasmid av dubbe1strängad DNA, kännetecknad av att vid införande i en lämplig värdcell i form av Escherichia coli ger värdcellen förmäga att ästadkomma uttryck av DNA, som kodar för en önskad, naturligt förekommande eukaryot polypep- tid med biologisk aktivitet och en aminosyrasekvens som i hu- - > vudsak är densamma som, men dock skiljer sig frän, den naturligt förekommande polypeptidens, och därvid ästadkommer produktion av polypeptiden, vilken plasmid i ordningen 5' tili 3' J omfattar följande: a) DNA, som i ordningen 5' tili 3' innefattar promotorerna 1 deo PI och den P2 i följd; b) DNA, som innefattar ett ribosomalt bindningsställe i syfte att ge mRNA, som transkriberas frän det DNA, som kodar för polypeptiden, förmäga att binda tili ribosomer inne i värdcel- :j Ien; c) valfritt, en DNA-sekvens som innehäller en eller bäda av en translations förstärkare för en AT-rik sekvens, och ett ställe för ett Ndel-restriktionsenzym; d) en startkodon ATG; och : e) DNA, som kodar för polypeptiden i en rätt fas med start- kodonen ATG; * : ·.. = · a ;*·*; och som dessutom innefattar en DNA-sekvens som omfattar ett • · . ursprung för repi ikä tionen, liksom ett ursprung (Ori) som vi- - ' * ; sats i figur l, frän en bakteriell plasmid med förmäga att au- „ * * tonomt kunna replikera i värdcellen samt en DNA-sekvens, som g ... innehäller en gen som är förenad med en selekterbar eller M identifierbar fenotypisk egenskap, liksom en selekterbar eller U · · · L *·[ * identif ierbar fenotypisk egenskap som är ampicillinresistens Ή (AmpR) , vilken uttryckes dä plasmiden förekommer i värdcellen. — · · 1J. · · a
2. Plasmid enligt patentkrav 1, kännetecknad av att värdcel- :9 · · ™ ] Ien av Escherichia coli omfattar sorterna S0732, S0744, ϋ :· : MC1061, S054O, S0928, S0929, S093O eller vildtypen (ATCC- fl accessionsnr 12 435). ra n M m 123 104429
3. Plasmid enligt patentkrav l, kännetecknad av att det ri-bosomala bindningsstället är det naturliga ribosomala bind-nignssället för den, som erhdlles frän deo-operonen; en mutation hos detta som har en förändring i sekvens tvä baser ned-ströms Shine-Dalgarno-sekvensen vid nukleotiderna -1 och -3 i : förhällande till A hos startkodonen; ell frän bakteriofag Xmed sekvensen: TAAGGAAATACTTACAT ATTC CTTTATGAATGTA; eller en mutant dl frän bakteriofag Xmed sekvensen: i TAAGGAAGTACTTACAT ATTCCTTCATGAATGTA; det naturliga ribosomala bindningsstället för β-laktamas, som _ erhälles frän pBR322; en syntetisk oligonukleotid med sekvensen: · · === AATTCGAGCGCAAGGAAACAGGCTCA • I · =—r GCTCGCGTTCCTTTGTCCGAGTAT; eller | • · — • · * • · ^ · - — ϊ en syntetisk oligonukleotid med sekvensen: _ • · — • · · — • · « • I : V: GACAAGCCTAGGTTTGTTTAACTTTAAGGAGAAATCATA , CTGTTCGGATCCAAACAAATTGAAATTCCTCTTTAGTAT. IM ----- • · • · · _
, 4. Plasmid enligt patentkrav l, kännetecknad av att den na- == t]· turligt förekommande polypeptiden omfattar humant koppar/zink- « · ϊ ” superoxiddismutas, humant mangan-superoxiddismutas, humant * II glutationperoxidas, humant tillväxthormon, bovint tillväxthor-;Υ· mon, tillväxthormon frän gris, humant apolipoprotein E eller f : en domän hos fibronektin. __ i I I I I 124 104429
5. Plasmid enligt patentkrav 4 för produktion av en polypep-tidanalog av humant koppar/zink-superoxiddismutas, kanneteck-nad av att den betecknats pMF-5531 som har den i figur 4 visa-: de restriktionskartan, pMF-5519 som har den i figur 5 visade restriktionskartan, pMF-558-26 som har den i figur 6 visade restriktionskartan, pMF-5536, pMF-5520 som har den i figur 7 visade restriktionskartan, pMF-2005 som har den i figur 9 visade restriktionskartan och som deponerats under ATCC acces-sionsnr 67 362, pMFS-5533A som har den i figur 17 visade restriktionskartan, eller pMFS-5538 som har den i figur 18 visade restriktionskartan, eller pMF-5534 som visats i figur 43 och deponerats i Escherichia no]i S093O (F*) under ATCC acces-. sionsnr 67703.
6. Plasmid enligt patentkrav 4, kännetecknad av att den an- vänds för produktion av en polypeptidanalog av humant till-ϊ växthormon, som betecknats pTVR-568-4 och som har den i figur 11 visade restriktionskartan.
7. Plasmid enligt patentkrav 4 för produktion av en polypep- j tid av bovint tillväxthormon, kännetecknad av att den beteck- !j nats pMFS-5600 som har den i figur 12 visade restriktionskar- 4 tan, pMFS-5627 som har den i figur 40 visade restriktionskar- V. tan, pMFS-5603 som har den i figur 41 visade restriktionskar tan, pMFS-5605 som har den i figur 42 visade restriktionskar- .. Ill ·* tan, eller pMFS-2006 som har den i figur 48 visade restrik- » · · · - '·*·’ tionskartan. • · • · · • · · r
· · ^ 8. Plasmid enligt patentkrav 4 för produktion av en polypep- 1. tid av tillväxthormon frän gris, kännetecknad av att den be- « tecknats pEFF-905 som har den i figur 38 visade restriktions- ~ · * ΪΪ ./ kartan, eller pEFF-920 som har den i figur 39 visade restrik- " · ♦ # « tionskartan. -- · · -J · · · m t a .
„ , :: : 9. Forfarande för produktion av en naturligt forekommande Tg polypeptid, kännetecknat av att det omfattar att läta ett sys- H tem värd-plasmid, som utformas av plasmiden enligt patentkrav i« 1, växa i en lämplig Escherichia coli -värd under betingelser, H m ia 125 104429 som medger produktion av polypeptiden, och att Stervinna den erhällna polypeptiden.
10. Förfarande enligt patentkrav 9, kannetecknat av att poly- - peptiden Sr humant koppar/zink-superoxiddismutas, humant till- växthormon, bovint tillväxthomon, tillväxthomon frSn gris, » humant mangan-superoxiddismutas-glutationperoxidas, humant glutationperoxidas, humant apolipoprotein E eller en domSn för fibronektin.
11. Förfarande enligt patentkrav 9, kännetecknat av att be- tingelserna omfattar svag luftning och tillväxt i ett medium I som innehäller en kolkalla som ej Sr glukos, fördelaktigt glycerol, fruktos, succinat, natriumlaktat eller natriummalat.
12. Förfarande enligt patentkrav 9, kännetecknat av att poly- ~ peptiden utsöndras i det medium, i vilket systemet värd-plas- mid växer, vid tillsats av en divalent metalljon till till- +2 +2 ” växtmediet, fördelaktigt Cu , Zn eller blandningar av dessa.
13. Förfarande enligt patentkrav 9, kännetecknat av att be- — tingelserna omfattar att initialt lSta cellerna av Rschprichia .:. noli växa i glukos och att efter det att glukosen förbrukats tillsätta en kolkälla, som ej Sr glukos och som fördelaktigt ^ • · 1 — ^ Sr fruktos, glycerol, succinat, natriumlaktat eller natriumina- ^ lat. i
• · · — « · « • · - - • · • · · -- *·'·' 14. Förfarande enligt patentkrav 9, kännetecknat av att be- ^ tingelserna ytterligare omfattar att lSta systemet värd-plas-··· — : mid växa vid cirka 30 °C. ··· • · · :_ • · · - — ♦ · - • · ___ • · • · • ·___ · · • · • t ---- • II III * • · __ ψ m · -- • f · • ·
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8615987A | 1987-08-14 | 1987-08-14 | |
| US8615987 | 1987-08-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI883749A0 FI883749A0 (fi) | 1988-08-12 |
| FI883749A FI883749A (fi) | 1989-02-15 |
| FI104429B true FI104429B (sv) | 2000-01-31 |
Family
ID=22196678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI883749A FI104429B (sv) | 1987-08-14 | 1988-08-12 | Uttrycksplasmider, som innefattar promotorer deo och bakterievärdceller, som innefattar dessa plasmider |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0303972B1 (sv) |
| JP (1) | JP2752092B2 (sv) |
| KR (1) | KR970000594B1 (sv) |
| AT (1) | ATE161888T1 (sv) |
| AU (1) | AU607249B2 (sv) |
| CA (1) | CA1309043C (sv) |
| DE (1) | DE3856101T2 (sv) |
| DK (1) | DK175537B1 (sv) |
| ES (1) | ES2112240T3 (sv) |
| FI (1) | FI104429B (sv) |
| GR (1) | GR3026136T3 (sv) |
| HU (1) | HU213418B (sv) |
| IL (1) | IL87409A (sv) |
| NO (1) | NO302185B1 (sv) |
| NZ (1) | NZ225760A (sv) |
| PT (1) | PT88271B (sv) |
| ZA (1) | ZA885983B (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0676472A1 (de) * | 1987-03-14 | 1995-10-11 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Humane Mangan-Superoxiddismutase (hMn-SOD) |
| US5260204A (en) * | 1987-03-14 | 1993-11-09 | Boehringer Ingelheim International Gmbh | Human manganese superoxide dismutase (hMn-SOD) |
| US5210180A (en) * | 1989-10-27 | 1993-05-11 | American Cyanamid Company | Enhancement of porcine somatotropin activity |
| US6165465A (en) * | 1990-05-15 | 2000-12-26 | American Cyanamid Company | Immunologic enhancement of the somatogenic effect of somatotropin with an antibody |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201116B (en) * | 1982-09-16 | 1990-09-28 | Benzon As Alfred | Process for producing plasmids having uncontrolled replication conduct under given circumstances |
-
1988
- 1988-08-09 NZ NZ225760A patent/NZ225760A/xx unknown
- 1988-08-11 EP EP88113071A patent/EP0303972B1/en not_active Expired - Lifetime
- 1988-08-11 IL IL87409A patent/IL87409A/en not_active IP Right Cessation
- 1988-08-11 AT AT88113071T patent/ATE161888T1/de not_active IP Right Cessation
- 1988-08-11 ES ES88113071T patent/ES2112240T3/es not_active Expired - Lifetime
- 1988-08-11 DE DE3856101T patent/DE3856101T2/de not_active Expired - Lifetime
- 1988-08-12 NO NO883611A patent/NO302185B1/no not_active IP Right Cessation
- 1988-08-12 HU HU884331A patent/HU213418B/hu unknown
- 1988-08-12 AU AU20982/88A patent/AU607249B2/en not_active Expired
- 1988-08-12 DK DK198804549A patent/DK175537B1/da not_active IP Right Cessation
- 1988-08-12 FI FI883749A patent/FI104429B/sv not_active IP Right Cessation
- 1988-08-12 ZA ZA885983A patent/ZA885983B/xx unknown
- 1988-08-12 PT PT88271A patent/PT88271B/pt not_active IP Right Cessation
- 1988-08-15 JP JP63203068A patent/JP2752092B2/ja not_active Expired - Lifetime
- 1988-08-15 CA CA000574717A patent/CA1309043C/en not_active Expired - Lifetime
- 1988-08-16 KR KR1019880010394A patent/KR970000594B1/ko not_active IP Right Cessation
-
1998
- 1998-02-12 GR GR980400309T patent/GR3026136T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE161888T1 (de) | 1998-01-15 |
| DK175537B1 (da) | 2004-11-29 |
| AU607249B2 (en) | 1991-02-28 |
| ES2112240T3 (es) | 1998-04-01 |
| HU213418B (en) | 1997-06-30 |
| EP0303972B1 (en) | 1998-01-07 |
| ZA885983B (en) | 1989-05-30 |
| IL87409A (en) | 1998-03-10 |
| JP2752092B2 (ja) | 1998-05-18 |
| NZ225760A (en) | 1991-02-26 |
| KR970000594B1 (ko) | 1997-01-14 |
| EP0303972A2 (en) | 1989-02-22 |
| HUT48681A (en) | 1989-06-28 |
| IL87409A0 (en) | 1989-01-31 |
| GR3026136T3 (en) | 1998-05-29 |
| DE3856101T2 (de) | 1998-07-23 |
| DK454988D0 (da) | 1988-08-12 |
| JPH01157391A (ja) | 1989-06-20 |
| AU2098288A (en) | 1989-03-09 |
| NO302185B1 (no) | 1998-02-02 |
| FI883749A0 (fi) | 1988-08-12 |
| DE3856101D1 (de) | 1998-02-12 |
| EP0303972A3 (en) | 1991-12-18 |
| PT88271B (pt) | 1995-07-18 |
| NO883611D0 (no) | 1988-08-12 |
| CA1309043C (en) | 1992-10-20 |
| PT88271A (pt) | 1989-06-30 |
| FI883749A (fi) | 1989-02-15 |
| NO883611L (no) | 1989-02-15 |
| KR890003953A (ko) | 1989-04-19 |
| DK454988A (da) | 1989-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4997916A (en) | Method for recovering a purified animal growth hormone or polypeptide analog thereof from a bacterial cell | |
| JP5634971B2 (ja) | 培地へのペプチドの直接発現 | |
| JP3359638B2 (ja) | 肺界面蛋白質ｓｐ−ｃの合成ペプチド類似体 | |
| JP4585435B2 (ja) | 条件複製起点をもつ環状ｄｎａ分子、それらの製造方法、及び、遺伝子治療におけるそれらの使用 | |
| SK704783A3 (en) | Dna sequences, recombinant molecules of dna and a method of producing polypeptides similar to sow growth hormone | |
| PT1356073E (pt) | Método de fermentação aperfeiçoado para a produção de produtos genéticos heterólogos em bactérias do ácido láctico | |
| FI94774C (sv) | Förfarande för framställning av cekropin och andra heterologa polypeptider i en bakterievärd genom att använda en araB-promotor och vid förfarandena användbara replikerbara expressionsmedel, genetiska konstruktioner och bakterier | |
| CZ285620B6 (cs) | Purifikovaná a izolovaná molekula DNA, analog beta-podjednotky tryptofan synthasy, tryptofan synthasa, prokaryontní nebo eukaryontní hostitelská buňka, způsob biosyntézy indolu a způsob biosyntézy indiga | |
| EP0483113B1 (en) | A method of producing an enzymatically active polypeptide analog of human Cu/Zn SOD | |
| JPH08289792A (ja) | ヒトマンガンスーパーオキシドジスムターゼｃＤＮＡ、その細菌中での発現及び酵素活性ヒトマンガンスーパーオキシドジスムターゼの回収方法 | |
| FI104429B (sv) | Uttrycksplasmider, som innefattar promotorer deo och bakterievärdceller, som innefattar dessa plasmider | |
| Rule et al. | Overproduction and nucleotide sequence of the respiratory D-lactate dehydrogenase of Escherichia coli | |
| FI93125B (sv) | Expression i E. coli av hybridpolypeptider som innehåller sekvensen för tillväxthormon frigörande faktorn | |
| FI116068B (sv) | Nytt selektionssystem, däri användbar vektor, bakteriestammar och förfarande för att välja celler | |
| US6010875A (en) | Expressions plasmids containing the deo promoter, and bacterial hosts containing the plasmids | |
| JPS5951793A (ja) | 新規クロ−ニングビヒクル | |
| US6054291A (en) | Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods | |
| US5527691A (en) | Expression vectors containing lambdapl promoter and T1 T2 rRNA termination sequence, plasmids containing the vectors, hosts containing the plasmids and related methods | |
| US5059529A (en) | Stabilized expression vectors containing λPL promoter and the gene for the cI434 repressor, plasmids containing the vectors, hosts containing the plasmids and related methods | |
| US5151364A (en) | Expression vectors containing lambdapl promoter, T1 T2 RRNA termination sequence, and origin of replication derived from a constitutive high copy number plasmid, and hosts containing the plasmids | |
| US5112744A (en) | Plasmids for the production of human Cu-Zn superoxide dismutase, bacterial hosts containing the plasmids and methods for production and recovery of such superoxide dismutase | |
| US5081020A (en) | Expression vectors containing λPL promoter, T1 T2 rRNA termination sequence and origin of replication derived from a constitutive high copy number plasmid hosts and related methods | |
| JPH0691833B2 (ja) | 利尿作用を有するポリペプチドの製造方法 | |
| JPH02219570A (ja) | ヒト５―リポキシゲナーゼの製造方法 | |
| JPH02501259A (ja) | 合成遺伝子を使用したサケ成長ホルモンの製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Owner name: SAVIENT PHARMACEUTICALS, INC. |
|
| MA | Patent expired |